Mandate

Vinge advises Surgical Science Sweden AB (publ) in connection with the acquisition of Mimic Technologies Inc and with a directed share issue

January 26, 2021 M&A

Vinge has advised Surgical Science Sweden AB (publ) (“Surgical Science”) in connection with its acquisition of all shares in Mimic Technologies Inc for an initial consideration of SEK 150 million with a maximum deferred contingent consideration of SEK 130 million.

In order to finance the acquisition, Surgical Science has carried out a directed share issue. The directed share issue comprised of 3,279,676 newly issued shares at a subscription price of SEK 98.30 per share, whereby Surgical Science will receive gross proceeds of approximately SEK 322 million before transaction related costs. The subscription price has been determined through an accelerated book‑building procedure and corresponds to a premium of approximately 1 per cent to the closing price of SEK 97.40 per share on 20 January 2021 on Nasdaq First North Growth Market.

Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Vinge’s team has consisted of Fredrik Sonander (M&A) and Edin Agic (Capital Markets).

Related

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025